Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema
-
Published:2024-01-02
Issue:2
Volume:16
Page:386-415
-
ISSN:1757-4684
-
Container-title:EMBO Molecular Medicine
-
language:en
-
Short-container-title:EMBO Mol Med
Author:
Creff JustineORCID, Lamaa Asalaa, Benuzzi Emeline, Balzan ElisaORCID, Pujol Francoise, Draia-Nicolau TangraORCID, Nougué Manon, Verdu LenaORCID, Morfoisse FlorentORCID, Lacazette EricORCID, Valet Philippe, Chaput Benoit, Gross FabianORCID, Gayon Regis, Bouillé Pascale, Malloizel-Delaunay Julie, Bura-Rivière AlessandraORCID, Prats Anne-CatherineORCID, Garmy-Susini BarbaraORCID
Abstract
AbstractSecondary lymphedema (LD) corresponds to a severe lymphatic dysfunction leading to the accumulation of fluid and fibrotic adipose tissue in a limb. Here, we identified apelin (APLN) as a powerful molecule for regenerating lymphatic function in LD. We identified the loss of APLN expression in the lymphedematous arm compared to the normal arm in patients. The role of APLN in LD was confirmed in APLN knockout mice, in which LD is increased and associated with fibrosis and dermal backflow. This was reversed by intradermal injection of APLN-lentivectors. Mechanistically, APLN stimulates lymphatic endothelial cell gene expression and induces the binding of E2F8 transcription factor to the promoter of CCBE1 that controls VEGF-C processing. In addition, APLN induces Akt and eNOS pathways to stimulate lymphatic collector pumping. Our results show that APLN represents a novel partner for VEGF-C to restore lymphatic function in both initial and collecting vessels. As LD appears after cancer treatment, we validated the APLN-VEGF-C combination using a novel class of nonintegrative RNA delivery LentiFlash® vector that will be evaluated for phase I/IIa clinical trial.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Alders M, Mendola A, Ades L, Al Gazali L, Bellini C, Dallapiccola B, Edery P, Frank U, Hornshuh F, Huisman SA et al (2013) Evaluation of clinical manifestations in patients with severe lymphedema with and without CCBE1 mutations. Mol Syndromol 4:107–113 2. Baik JE, Park HJ, Kataru RP, Savetsky IL, Ly CL, Shin J, Encarnacion EM, Cavali MR, Klang MG, Riedel E et al (2022) TGF-beta1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation. Clin Transl Med 12:e758 3. Bernier-Latmani J, Cisarovsky C, Mahfoud S, Ragusa S, Dupanloup I, Barras D, Renevey F, Nassiri S, Anderle P, Squadrito ML et al (2022) Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth. Nat Cardiovasc Res 1:476–490 4. Berta J, Hoda MA, Laszlo V, Rozsas A, Garay T, Torok S, Grusch M, Berger W, Paku S, Renyi-Vamos F et al (2014) Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget 5:4426–4437 5. Bonet F, Inacio JM, Bover O, Anez SB, Belo JA (2022) CCBE1 in cardiac development and disease. Front Genet 13:836694
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|